<span item_type="fundamental" item_id="584e371775db2d3d8bd75988a9af86cf" counter_id="ST/US/SLXNW" env="prod"></span><span item_type="announcement" item_id="627366136978084865" env="prod"></span><p>Revenue: As of FY2025, the actual value is USD 0.</p><p>EPS: As of FY2025, the actual value is USD -8.96.</p><p>EBIT: As of FY2025, the actual value is USD -11.77 M.</p><p></p><h4>Net Loss</h4><p>Silexion Therapeutics Corp reported a net loss of - $11.9 million for the year ended December 31, 2025, an improvement from a net loss of - $16.5 million in 2024, with an accumulated deficit of - $55.2 million as of December 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/zk2634529.htm"></span></p><h4>Research and Development Expenses</h4><p>Research and development (R&amp;D) expenses increased by 22.4% to $7.1 million in 2025 from $5.8 million in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/zk2634529.htm"></span> This increase was primarily due to a $3.1 million rise in subcontractors and consultants expenses for GMP production and formulation development, and a $0.6 million increase in payroll and related expenses, partially offset by a - $2.4 million decrease in non-cash share-based compensation expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/zk2634529.htm"></span></p><h4>General and Administrative Expenses</h4><p>General and administrative (G&amp;A) expenses decreased by 33.8% to $4.5 million in 2025 from $6.8 million in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/zk2634529.htm"></span> This reduction mainly resulted from a - $3.3 million decrease in non-cash share-based compensation expenses, partly offset by a $0.5 million increase in professional services and a $0.4 million increase in payroll and related expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/zk2634529.htm"></span></p><h4>Financial Expenses, Net</h4><p>Financial expenses, net, decreased by 92.3% to $0.3 million in 2025 from $3.9 million in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/zk2634529.htm"></span> This significant decrease was mainly due to a - $4.8 million one-time loss recognized upon the Business Combination in August 2024, partially offset by a $1.4 million revaluation income from financial instruments.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/zk2634529.htm"></span></p><h4>Cash Flow from Operating Activities</h4><p>Net cash used in operating activities increased to - $10.8 million in 2025, up from - $8.4 million in 2024, primarily due to increased payments for R&amp;D subcontractors, consultants, payroll, and professional services.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/zk2634529.htm"></span></p><h4>Cash Flow from Financing Activities</h4><p>Net cash provided by financing activities increased to $15.6 million in 2025, from $5.1 million in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/zk2634529.htm"></span> This was largely driven by $11.0 million (net) from public offerings, $2.6 million from warrant exercises, and $5.0 million (net) from warrant exercise inducement transactions, partially offset by a - $0.4 million decrease in payments under the EarlyBird Convertible Note and a - $2.3 million decrease in cash from 2024 financing transactions.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/zk2634529.htm"></span></p><h4>Cash and Cash Equivalents</h4><p>As of December 31, 2025, cash and cash equivalents totaled $6.0 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/zk2634529.htm"></span></p><h4>Grants from Israeli Innovation Authority (IIA)</h4><p>As of December 31, 2025, Silexion Therapeutics Corp had received IIA royalty-bearing grants totaling approximately $5.8 million, with a potential royalty payable amount of $6.7 million including interest.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/zk2634529.htm"></span></p><h4>SIL204 Operational Milestones</h4><p>In 2025, Silexion Therapeutics Corp completed toxicology studies for SIL204, confirming no systemic organ toxicity, and made progress on manufacturing GMP API and formulation development.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/zk2634529.htm"></span> Regulatory clearance was obtained from BfArM in Germany for the Phase <sup>2</sup>⁄<sub>3</sub> trial design, and an application was submitted to the Israeli Ministry of Health to initiate the adaptive Phase <sup>2</sup>⁄<sub>3</sub> trial.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/zk2634529.htm"></span></p><h4>Outlook / Guidance</h4><p>Silexion Therapeutics Corp expects to initiate the first part of its Phase <sup>2</sup>⁄<sub>3</sub> clinical studies for SIL204 in the second quarter of 2026, with plans for applications in additional European Union countries and an investigational new drug application (IND) to the U.S. FDA in early 2027.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/zk2634529.htm"></span> The company anticipates requiring substantial additional funding to finance operations and expand its business and pipeline, as current cash and cash equivalents are only sufficient for several months.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/zk2634529.htm"></span> Additionally, it plans to apply for Orphan Drug Designation in both the U.S. and EU in the first half of 2027.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/zk2634529.htm"></span></p>

SILEXION THERAPEUTICS CORP C/WTS EXP 15/08/2029 (TO PUR COM) | 10-K: FY2025 Revenue: USD 0